First Thing, Daily Maverick's flagship newsletter

Join the 230 000 South Africans who read First Thing newsletter.

AstraZeneca Covid-19 vaccine shows 74% efficacy in larg...

Newsdeck

Newsdeck

AstraZeneca Covid-19 vaccine shows 74% efficacy in large U.S. trial

Empty vials of the AstraZeneca Plc Covid-19 vaccine arranged at a vaccination center set up in Karachi, Pakistan, on Tuesday, May 11, 2021. (Photo: Asim Hafeez/Bloomberg via Getty Images)
By Reuters
30 Sep 2021 0

CHICAGO, Sept 29 (Reuters) - AstraZeneca Plc's Covid-19 vaccine demonstrated 74% efficacy at preventing symptomatic disease, a figure that increased to 83.5% in people aged 65 and older, according to long-awaited results of the company's U.S. clinical trial published on Wednesday.

By Julie Steenhuysen

Overall efficacy of 74% was lower than the interim 79% figure reported by the British drugmaker in March, a result AstraZeneca revised days later to 76% after a rare public rebuke from health officials that the figure was based on “outdated information.”

The data looked at more than 26,000 volunteers in the United States, Chile and Peru, who received two doses of the vaccine spaced about a month apart. The results were published in the New England Journal of Medicine.

There were no cases of severe or critical symptomatic COVID-19 among the more than 17,600 participants who got the vaccine, compared with 8 such cases among the 8,500 volunteers who got the placebo. There were also two deaths in the placebo group but none among those who received the vaccine.

“I was pleasantly surprised,” Dr. Anna Durbin, a vaccine researcher at Johns Hopkins University and one of the study’s investigators, said of the overall result. “It was also highly protective against severe disease and hospitalization,” she said.

There were no cases of a rare but serious blood clotting side effect called thrombosis with thrombocytopenia that has been linked to the AstraZeneca vaccine developed with Oxford University researchers.

AstraZeneca said in late July it planned to file for full approval with the U.S. Food and Drug Administration, rather than seek emergency use authorization. Chief Executive Pascal Soriot told a media briefing at the time he hoped the vaccine could still play a role in the United States, even though the process was taking longer than expected.

The company is exploring booster doses for people who have already been vaccinated with two doses of either its own shot or mRNA-based vaccines from Pfizer/BioNTech or Moderna.

The vaccine, known as Vaxzevria, is authorized for use in more than 170 countries. A spokesperson said the company expects to file for U.S. approval later this year.

Durbin said she does not expect Vaxzevria to be used much in the United States, but securing FDA approval “does give them gravitas.” (Reporting by Julie Steenhuysen Editing by Bill Berkrot)

Information pertaining to Covid-19, vaccines, how to control the spread of the virus and potential treatments is ever-changing. Under the South African Disaster Management Act Regulation 11(5)(c) it is prohibited to publish information through any medium with the intention to deceive people on government measures to address COVID-19. We are therefore disabling the comment section on this article in order to protect both the commenting member and ourselves from potential liability. Should you have additional information that you think we should know, please email [email protected]

Gallery

Please peer review 3 community comments before your comment can be posted